| Followers | 14 |
| Posts | 1740 |
| Boards Moderated | 0 |
| Alias Born | 06/14/2018 |
Sunday, January 27, 2019 2:10:48 AM
These January shorts make no sense at all.
In January they were shorted between $5.50 and $6.70.
NOW, how much lower does anybody think it can go??
I could understand MRKR being shorted when it was at $12.50 or $11.00.
BUT, to short MRKR at $6 seems like a giant risk with very little gain.
Here's the deal with shorting.
We all know it the opposite of buying long, BUT it is ALSO opposite in it's risk/reward value.
When buying long, let's say you invest $1000. The MOST money you could possible lose is $1000 (if it goes to zero), but you have the potential to make $10,000 or $100,000.
Shorting is the opposite risk/reward.
You short a stock with a $1000 investment. The MOST money you can make is $1000 (if it goes to zero), but you have the potential to LOSE $10,000 or $100,000 (if it jumps up crazy).
Unless all of us who believe in MRKR's potential are just crazy and deceiving ourselves, I can not understand why anyone would short MRKR at $6.00 or $6.50.
It seems like a bet with very little upside and huge downside.
In January they were shorted between $5.50 and $6.70.
NOW, how much lower does anybody think it can go??
I could understand MRKR being shorted when it was at $12.50 or $11.00.
BUT, to short MRKR at $6 seems like a giant risk with very little gain.
Here's the deal with shorting.
We all know it the opposite of buying long, BUT it is ALSO opposite in it's risk/reward value.
When buying long, let's say you invest $1000. The MOST money you could possible lose is $1000 (if it goes to zero), but you have the potential to make $10,000 or $100,000.
Shorting is the opposite risk/reward.
You short a stock with a $1000 investment. The MOST money you can make is $1000 (if it goes to zero), but you have the potential to LOSE $10,000 or $100,000 (if it jumps up crazy).
Unless all of us who believe in MRKR's potential are just crazy and deceiving ourselves, I can not understand why anyone would short MRKR at $6.00 or $6.50.
It seems like a bet with very little upside and huge downside.
Recent MRKR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 09:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:30:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:08:49 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/20/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:05:49 PM
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results • GlobeNewswire Inc. • 03/18/2026 09:31:30 PM
- Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:06:45 PM
- Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology • GlobeNewswire Inc. • 01/26/2026 12:00:00 PM
- Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:15 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/17/2025 09:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:20:47 PM
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:29:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:36:59 PM
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors • GlobeNewswire Inc. • 11/05/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:03:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 09:54:39 PM
- Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting • GlobeNewswire Inc. • 11/03/2025 02:15:00 PM
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program • GlobeNewswire Inc. • 10/06/2025 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:30:37 AM
